Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

177Lu−SN201 nanoparticle shows superior anti−tumor efficacy over conventional cancer drugs in 4T1 orthotopic model

Lekmeechai, Sujinna LU ; Pietras, Kristian LU orcid and Axelsson, Oskar (2024) In Investigational New Drugs 42(4). p.471-477
Abstract

In the current in-vivo study we demonstrate the potential of the radiolabeled nanoparticle 177Lu-SN201 as an effective anticancer treatment, as evidenced by significantly prolonged survival and reduced tumor burden in the aggressive, triple negative 4T1 murine breast cancer model. We show with high statistical significance that 177Lu-SN201 is superior at suppressing the tumor growth not only compared to vehicle but also to the commonly used cancer drugs paclitaxel, niraparib, carboplatin, and the combination of the immune checkpoint inhibitors anti PD-1 and anti-CTLA-4. The dosing of the standard drugs were based on examples in the literature where good effects have been seen in various mouse models. The treatment... (More)

In the current in-vivo study we demonstrate the potential of the radiolabeled nanoparticle 177Lu-SN201 as an effective anticancer treatment, as evidenced by significantly prolonged survival and reduced tumor burden in the aggressive, triple negative 4T1 murine breast cancer model. We show with high statistical significance that 177Lu-SN201 is superior at suppressing the tumor growth not only compared to vehicle but also to the commonly used cancer drugs paclitaxel, niraparib, carboplatin, and the combination of the immune checkpoint inhibitors anti PD-1 and anti-CTLA-4. The dosing of the standard drugs were based on examples in the literature where good effects have been seen in various mouse models. The treatment is reasonably well-tolerated, as indicated by clinical chemistry of liver and renal function through the measurement of glutamate pyruvate alanine aminotransferase, alanine amino transferase, blood urea nitrogen, and creatinine levels in plasma samples, despite some weight loss. Overall, 177Lu-SN201 presents as a promising therapeutic candidate for cancer treatment.

(Less)
Please use this url to cite or link to this publication:
author
; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Lu, Lu-SN201, Cancer, Nanoparticle, Radiotherapy, Targeted radiotherapy
in
Investigational New Drugs
volume
42
issue
4
pages
7 pages
publisher
Springer
external identifiers
  • pmid:38837077
  • scopus:85195308657
ISSN
0167-6997
DOI
10.1007/s10637-024-01450-2
language
English
LU publication?
yes
id
1d3ec6a5-2954-49a2-98ed-2fd5dc0b3c2c
date added to LUP
2024-09-12 15:39:21
date last changed
2024-09-12 15:39:21
@article{1d3ec6a5-2954-49a2-98ed-2fd5dc0b3c2c,
  abstract     = {{<p>In the current in-vivo study we demonstrate the potential of the radiolabeled nanoparticle <sup>177</sup>Lu-SN201 as an effective anticancer treatment, as evidenced by significantly prolonged survival and reduced tumor burden in the aggressive, triple negative 4T1 murine breast cancer model. We show with high statistical significance that <sup>177</sup>Lu-SN201 is superior at suppressing the tumor growth not only compared to vehicle but also to the commonly used cancer drugs paclitaxel, niraparib, carboplatin, and the combination of the immune checkpoint inhibitors anti PD-1 and anti-CTLA-4. The dosing of the standard drugs were based on examples in the literature where good effects have been seen in various mouse models. The treatment is reasonably well-tolerated, as indicated by clinical chemistry of liver and renal function through the measurement of glutamate pyruvate alanine aminotransferase, alanine amino transferase, blood urea nitrogen, and creatinine levels in plasma samples, despite some weight loss. Overall, <sup>177</sup>Lu-SN201 presents as a promising therapeutic candidate for cancer treatment.</p>}},
  author       = {{Lekmeechai, Sujinna and Pietras, Kristian and Axelsson, Oskar}},
  issn         = {{0167-6997}},
  keywords     = {{Lu; Lu-SN201; Cancer; Nanoparticle; Radiotherapy; Targeted radiotherapy}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{471--477}},
  publisher    = {{Springer}},
  series       = {{Investigational New Drugs}},
  title        = {{<sup>177</sup>Lu−SN201 nanoparticle shows superior anti−tumor efficacy over conventional cancer drugs in 4T1 orthotopic model}},
  url          = {{http://dx.doi.org/10.1007/s10637-024-01450-2}},
  doi          = {{10.1007/s10637-024-01450-2}},
  volume       = {{42}},
  year         = {{2024}},
}